Coronary Artery Disease (CAD) (Ischemic Heart Disease) accounted for a 12.2% share of the global clinical trials within the Cardiovascular therapy area in 2021, registering a decrease of 2.3% when compared with the last ten-year average of 14.5% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Non-industry sponsored trials outnumber industry sponsored trials for Coronary Artery Disease
Industry sponsored trials held a 37.6% share of all the clinical trials for Coronary Artery Disease indication in 2021, registering an increase of 6.3% when compared with the ten-year average of 31.3%. Non-industry sponsored trials accounted for a 62.4% share in 2021, marking a decrease of 6.3% over the ten-year average of 68.7%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top regions of industry sponsored Coronary Artery Disease trials
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAsia-Pacific was the top region for industry sponsored Coronary Artery Disease trials, accounting for a 55.2% share in 2021, when compared with the five-year average of 68.3% and ten-year average of 54.6%.
Europe was at the second position with a 29.9% share in 2021, over the five-year average of 30.9% and ten-year average of 40.7%, followed by Middle East and Africa with a 9.2% share in 2021, as against five-year and ten-year averages of 4.4% and 7.6% respectively.
North America stood fourth with a 6.9% share in 2021, compared with the five-year average of 13.5% and ten-year average of 22.0%, followed by South and Central America with a 0.0% share in 2021, over five-year and ten-year averages of 5.6% and 7.8% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for industry sponsored Coronary Artery Disease trials, accounting for a 35.6% share in 2021, as against the five-year average of 40.9% and ten-year average of 26.8%.
Russia held an 18.4% share in 2021, over the five-year average of 12.5% and ten-year average of 17.4%, followed by Iran with a 9.2% share in 2021, compared with the five-year and ten-year averages of 1.2% and 0.9% respectively.
The US held a 6.9% share in 2021, as against the five-year average of 12.9% and ten-year average of 20.4%.
Thailand held a 5.7% share in 2021, over the five-year and ten-year averages of 7.1% and 4.6% respectively.
Top regions of non-industry sponsored Coronary Artery Disease trials
Asia-Pacific was the top region for non-industry sponsored Coronary Artery Disease trials, accounting for a 65.9% share in 2021 when compared with the five-year average of 54.7% and ten-year average of 50.4%.
Europe was at the second position with an 18.1% share in 2021, over the five-year and ten-year averages of 20.0% and 25.2% respectively, followed by North America with a 7.2% share in 2021, as against the five-year average of 9.7% and ten-year average of 12.4%.
Middle East and Africa stood at the fourth position with a 6.5% share in 2021, compared with the five-year average of 14.8% and ten-year average of 13.1%, followed by South and Central America with a 2.9% share in 2021, over the five-year and ten-year averages of 2.8% and 2.5% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for non-industry sponsored Coronary Artery Disease trials, accounting for a 41.3% share in 2021, as against the five-year average of 32.0% and ten-year average of 24.5%.
South Korea held an 8.7% share in 2021, over the five-year average of 7.9% and ten-year average of 8.4%, followed by Iran with a 5.1% share, compared with the five-year and ten-year averages of 12.8% and 10.5% respectively.
The US held a 4.3% share in 2021, as against the five-year average of 8.1% and ten-year average of 10.1%.
Australia held a 3.6% share in 2021, over the five-year average of 2.0% and ten-year average of 2.1%.
Phase I trials lead industry sponsored clinical trials for Coronary Artery Disease in 2021
Phase I trials held a 54.3% share of industry sponsored clinical trials for Coronary Artery Disease in 2021, over the five-year average of 50.8% and ten-year average of 41.6%.
Phase II trials held a 21.7% share in 2021, as against the five-year average of 18.3% and ten-year average of 21.5%. Phase IV trials held an 18.5% share in 2021, compared with the five-year and ten-year averages of 23.1% and 23.8% respectively.
Phase III trials held a 5.4% share in 2021, over the five-year average of 7.8% and ten-year average of 13.1%.
Phase IV trials lead non-industry sponsored clinical trials for Coronary Artery Disease in 2021
Phase IV trials held a 47.1% share of non-industry sponsored clinical trials for Coronary Artery Disease in 2021, over the five-year average of 47.4% and ten-year average of 45.7%.
Phase II trials held a 23.5% share in 2021, as against the five-year average of 31.3% and ten-year average of 32.6%. Phase III trials held a 17.6% share, compared with the five-year and ten-year averages of 15.6% and 16.0% respectively.
Phase I trials held a 11.8% share in 2021, over the five-year average of 5.7% and ten-year average of 5.8%.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
